JP2019147825A5 - - Google Patents

Download PDF

Info

Publication number
JP2019147825A5
JP2019147825A5 JP2019091813A JP2019091813A JP2019147825A5 JP 2019147825 A5 JP2019147825 A5 JP 2019147825A5 JP 2019091813 A JP2019091813 A JP 2019091813A JP 2019091813 A JP2019091813 A JP 2019091813A JP 2019147825 A5 JP2019147825 A5 JP 2019147825A5
Authority
JP
Japan
Prior art keywords
salt
hydroxy
compound according
bromine
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019091813A
Other languages
English (en)
Japanese (ja)
Other versions
JP6681498B2 (ja
JP2019147825A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019147825A publication Critical patent/JP2019147825A/ja
Publication of JP2019147825A5 publication Critical patent/JP2019147825A5/ja
Application granted granted Critical
Publication of JP6681498B2 publication Critical patent/JP6681498B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019091813A 2014-05-13 2019-05-15 重水素化ヘテロ環式化合物及びイメージング剤としてのその使用 Active JP6681498B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13
US61/992,717 2014-05-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016567651A Division JP6529986B2 (ja) 2014-05-13 2015-05-12 重水素化ヘテロ環式化合物及びイメージング剤としてのその使用

Publications (3)

Publication Number Publication Date
JP2019147825A JP2019147825A (ja) 2019-09-05
JP2019147825A5 true JP2019147825A5 (enExample) 2019-11-14
JP6681498B2 JP6681498B2 (ja) 2020-04-15

Family

ID=53269446

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016567651A Active JP6529986B2 (ja) 2014-05-13 2015-05-12 重水素化ヘテロ環式化合物及びイメージング剤としてのその使用
JP2019091813A Active JP6681498B2 (ja) 2014-05-13 2019-05-15 重水素化ヘテロ環式化合物及びイメージング剤としてのその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016567651A Active JP6529986B2 (ja) 2014-05-13 2015-05-12 重水素化ヘテロ環式化合物及びイメージング剤としてのその使用

Country Status (21)

Country Link
US (4) US10076581B2 (enExample)
EP (2) EP3901145A1 (enExample)
JP (2) JP6529986B2 (enExample)
KR (2) KR102530129B1 (enExample)
CN (2) CN110483522B (enExample)
AU (2) AU2015261008B2 (enExample)
CA (1) CA2948721C (enExample)
DK (1) DK3143011T3 (enExample)
ES (1) ES2867814T3 (enExample)
HR (1) HRP20210641T1 (enExample)
HU (1) HUE053939T2 (enExample)
IL (3) IL280791B2 (enExample)
LT (1) LT3143011T (enExample)
MX (2) MX384604B (enExample)
PL (1) PL3143011T3 (enExample)
PT (1) PT3143011T (enExample)
RS (1) RS61810B1 (enExample)
RU (1) RU2696492C2 (enExample)
SG (2) SG10201805628TA (enExample)
SI (1) SI3143011T1 (enExample)
WO (1) WO2015173225A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948721C (en) * 2014-05-13 2023-03-28 F. Hoffmann-La Roche Ag Deuterated compounds and uses thereof
JP7197476B2 (ja) 2016-07-22 2022-12-27 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
JP7059270B2 (ja) 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
JP7286539B2 (ja) * 2016-11-01 2023-06-05 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化protac、および関連使用方法
CA3072362A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
WO2019145292A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
US11306089B2 (en) 2018-01-24 2022-04-19 Life Molecular Imaging Limited Gamma-carboline compounds for the detection of Tau aggregates
US11623927B2 (en) 2018-03-02 2023-04-11 The Trustees Of The University Of Pennsylvania Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules
SG11202011299PA (en) 2018-05-17 2020-12-30 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
MY209034A (en) 2018-10-05 2025-06-17 Forma Therapeutics Inc Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7119978B2 (ja) * 2018-12-20 2022-08-17 オムロン株式会社 制御装置およびプログラム
CN114423763B (zh) * 2019-05-09 2025-01-21 豪夫迈·罗氏有限公司 咪唑并[1,2-a]嘧啶的区域选择性合成
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
CN113526526A (zh) * 2021-07-12 2021-10-22 苏州大学 氘代氨制备方法及以其作为氘源参与的氘代反应
CA3228359A1 (en) 2021-08-27 2023-03-02 Genentech, Inc. Methods of treating tau pathologies
EP4536358A1 (en) 2022-06-13 2025-04-16 Genentech Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
WO2025155625A1 (en) * 2024-01-16 2025-07-24 Eli Lilly And Company Novel compounds for tau imaging
CN118957609B (zh) * 2024-07-23 2025-09-09 无锡绿能电合科技有限公司 一种氟代芳环的氘代方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE76515C (de) F. MORA in Mailand Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff
DD76515A (enExample) *
EP1340759A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
HUE032660T2 (en) * 2006-03-30 2017-10-30 Univ Pennsylvania Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ[d][1,3]ジオキソールおよびその誘導体の合成
SI2247558T2 (sl) 2008-02-14 2024-10-30 Eli Lilly And Company Nova kontrastna sredstva za zaznavanje nevroloških disfunkcij
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US20100144657A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US8491869B2 (en) 2009-03-23 2013-07-23 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP2450332A1 (en) 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
NZ610315A (en) * 2010-11-15 2015-08-28 Univ Leuven Kath Antiviral condensed heterocyclic compounds
WO2013176698A1 (en) * 2012-05-22 2013-11-28 Eli Lilly And Company Carboline and carbazole based imaging agents for detecting neurological dysfunction
CN105358558B (zh) * 2013-10-08 2017-09-26 豪夫迈·罗氏有限公司 作为tau‑pet‑配体的二氮杂咔唑衍生物
CA2948721C (en) 2014-05-13 2023-03-28 F. Hoffmann-La Roche Ag Deuterated compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2019147825A5 (enExample)
JP2022043078A5 (enExample)
JP2019207442A5 (enExample)
JP2022078315A5 (enExample)
JP2018529687A5 (enExample)
JP2016148024A5 (enExample)
JP2018024670A5 (enExample)
JP2010174033A5 (enExample)
JP2013505929A5 (enExample)
JP2010168249A5 (enExample)
JP2018525327A5 (enExample)
JP2010534247A5 (enExample)
JP2009138000A5 (enExample)
JP2019504839A5 (enExample)
JP2009530489A5 (enExample)
JP2010501516A5 (enExample)
JP2015527345A5 (enExample)
JP2016513709A5 (enExample)
JP2016125056A5 (enExample)
JP2020073474A5 (enExample)
JPWO2021220648A5 (enExample)
JP2010534246A5 (enExample)
JP2024054192A5 (enExample)
JP2009179634A5 (enExample)
JP2019189529A5 (enExample)